The stock of Genmab ADR (GMAB) has seen a -5.59% decrease in the past week, with a -10.19% drop in the past month, and a -24.32% decrease in the past quarter. The volatility ratio for the week is 1.80%, and the volatility levels for the past 30 days are at 1.81% for GMAB. The simple moving average for the last 20 days is -7.97% for GMAB’s stock, with a simple moving average of -24.11% for the last 200 days.
Is It Worth Investing in Genmab ADR (NASDAQ: GMAB) Right Now?
The price-to-earnings ratio for Genmab ADR (NASDAQ: GMAB) is 19.70x, which is above its average ratio. Moreover, the 36-month beta value for GMAB is 0.97. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GMAB is 635.13M and currently, short sellers hold a 0.37% of that float. On November 21, 2024, GMAB’s average trading volume was 988.92K shares.
GMAB) stock’s latest price update
The stock of Genmab ADR (NASDAQ: GMAB) has decreased by -0.24 when compared to last closing price of 20.50.Despite this, the company has seen a loss of -5.59% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-09 that Genmab A/S (GMAB) Q3 2024 Earnings Conference Call November 6, 2024 12:00 PM ET Company Participants Jan van de Winkel – CEO Brad Bailey – EVP and Chief Commercial Officer Anthony Pagano – CFO Judith Klimovsky – Chief Development Officer Tahamtan Ahmadi – Chief Medical Officer Conference Call Participants Jonathan Chang – LeeRink Partners Paul Jeng – Guggenheim Securities, LLC Zain Ebrahim – JPMorgan Chase Suzanne van Voorthuizen – Kempen & Co. Xian Deng – UBS Yaron Werber – TD Securities Asthika Goonewardene – Truist Securities Yifeng Liu – HSBC Matthew Phipps – William Blair Alistair Campbell – RBC Capital Markets Vikram Purohit – Morgan Stanley Etzer Darout – BMO Capital Markets Operator Hello, and welcome to Genmab’s Financial Results Conference Call for the First Nine Months of 2024. As a reminder, this conference call is being recorded.
Analysts’ Opinion of GMAB
Morgan Stanley, on the other hand, stated in their research note that they expect to see GMAB reach a price target of $31. The rating they have provided for GMAB stocks is “Equal-Weight” according to the report published on September 04th, 2024.
GMAB Trading at -12.62% from the 50-Day Moving Average
After a stumble in the market that brought GMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.80% of loss for the given period.
Volatility was left at 1.81%, however, over the last 30 days, the volatility rate increased by 1.80%, as shares sank -10.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.06% lower at present.
During the last 5 trading sessions, GMAB fell by -5.59%, which changed the moving average for the period of 200-days by -27.35% in comparison to the 20-day moving average, which settled at $22.22. In addition, Genmab ADR saw -35.77% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GMAB
Current profitability levels for the company are sitting at:
- 0.32 for the present operating margin
- 0.96 for the gross margin
The net margin for Genmab ADR stands at 0.23. The total capital return value is set at 0.18. Equity return is now at value 14.67, with 12.34 for asset returns.
Currently, EBITDA for the company is 5.56 billion with net debt to EBITDA at -0.81. When we switch over and look at the enterprise to sales, we see a ratio of 4.38. The receivables turnover for the company is 3.13for trailing twelve months and the total asset turnover is 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.17.
Conclusion
To wrap up, the performance of Genmab ADR (GMAB) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
